Developing a vaccine to protect against hypervirulent strains of group A streptococcus

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1083548

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Epidemic invasive GAS disease is associated with the emergence of the globally disseminated M1T1 clone and is linked to the mutation in the CovR/S regulator. This mutation leads to over- expression of SpyCEP and inhibits recruitment of neutrophils to the site of infection. Inclusion of an immunogenic fragment of SpyCEP into our current vaccine would enhance its efficacy and lead to the development of a vaccine with a wider coverage and better protective efficacy against hypervirulent GAS strains

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $536,850.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Bacteriology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Aboriginal health | cardiovascular sequelae | necrotising fasciitis | vaccine design | vaccine development

Related Links